Research programme : skin disorders therapeutics - Chemiderm/Harvard

Drug Profile

Research programme : skin disorders therapeutics - Chemiderm/Harvard

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator Chemiderm Inc
  • Developer Chemiderm Inc; Harvard University
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Atopic dermatitis; Psoriasis

Most Recent Events

  • 19 Nov 2015 Early research in Psoriasis in USA (Topical)
  • 19 Nov 2015 Early research in Atopic dermatitis in USA (Topical)
  • 19 Nov 2015 Chemiderm and Harvard University agree to develop compounds for Psoriasis and Atopic dermatitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top